Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications

被引:10
|
作者
Friberger, Ida [1 ]
Jussing, Emma [2 ,3 ]
Han, Jinming [1 ,4 ]
Goos, Jeroen A. C. M. [1 ,2 ,3 ]
Siikanen, Jonathan [2 ,5 ]
Kaipe, Helen [6 ,7 ]
Lambert, Melanie [8 ]
Harris, Robert A. [1 ,4 ]
Samen, Erik [2 ,3 ]
Carlsten, Mattias [8 ,9 ]
Holmin, Staffan [1 ,10 ]
Tran, Thuy A. [1 ,2 ,3 ]
机构
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[2] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Radiopharm, Stockholm, Sweden
[4] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Med Radiat Phys & Nucl Med, Stockholm, Sweden
[6] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[7] Karolinska Univ Hosp, Dept Clin Immunol & Transfus Med, Stockholm, Sweden
[8] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[9] Karolinska Univ Hosp, Ctr Cell Therapy & Allogene Stem Cell Transplanta, Stockholm, Sweden
[10] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Cell labelling; Cell tracking; Zr-89; Oxine; Deferoxamine; PET; Imaging; DONOR LYMPHOCYTE INFUSION; DECIDUAL STROMAL CELLS; TRACKING; LEUKOCYTES; PET; CYTOTOXICITY; LEUKEMIA; RELAPSE;
D O I
10.1007/s11307-021-01622-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background There is a need to better characterise cell-based therapies in preclinical models to help facilitate their translation to humans. Long-term high-resolution tracking of the cells in vivo is often impossible due to unreliable methods. Radiolabelling of cells has the advantage of being able to reveal cellular kinetics in vivo over time. This study aimed to optimise the synthesis of the radiotracers [Zr-89]Zr-oxine (8-hydroxyquinoline) and [Zr-89]Zr-DFO-NCS (p-SCN-Bn-Deferoxamine) and to perform a direct comparison of the cell labelling efficiency using these radiotracers. Procedures Several parameters, such as buffers, pH, labelling time and temperature, were investigated to optimise the synthesis of [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS in order to reach a radiochemical conversion (RCC) of >95 % without purification. Radio-instant thin-layer chromatography (iTLC) and radio high-performance liquid chromatography (radio-HPLC) were used to determine the RCC. Cells were labelled with [Zr-89]Zr-oxine or [Zr-89]Zr-DFO-NCS. The cellular retention of Zr-89 and the labelling impact was determined by analysing the cellular functions, such as viability, proliferation, phagocytotic ability and phenotypic immunostaining. Results The optimised synthesis of [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS resulted in straightforward protocols not requiring additional purification. [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS were synthesised with an average RCC of 98.4 % (n = 16) and 98.0 % (n = 13), respectively. Cell labelling efficiencies were 63.9 % (n = 35) and 70.2 % (n = 30), respectively. Zr-89 labelling neither significantly affected the cell viability (cell viability loss was in the range of 1-8 % compared to its corresponding non-labelled cells, P value > 0.05) nor the cells' proliferation rate. The phenotype of human decidual stromal cells (hDSC) and phagocytic function of rat bone-marrow-derived macrophages (rMac) was somewhat affected by radiolabelling. Conclusions Our study demonstrates that [Zr-89]Zr-oxine and [Zr-89]Zr-DFO-NCS are equally effective in cell labelling. However, [Zr-89]Zr-oxine was superior to [Zr-89]Zr-DFO-NCS with regard to long-term stability, cellular retention, minimal variation between cell types and cell labelling efficiency.
引用
收藏
页码:952 / 962
页数:11
相关论文
共 50 条
  • [31] Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP)
    Nakaigawa, Noboru
    Hasumi, Hisashi
    Utsunomiya, Daisuke
    Yoshida, Keisuke
    Ishiwata, Yoshinobu
    Oka, Takashi
    Hayward, Colin
    Makiyama, Kazuhide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (08) : 873 - 879
  • [32] The Feasibility of 68Ga Replacing 89Zr for CAR T Cell PET Monitoring
    Wang, X.
    Wang, Y.
    Pan, D.
    Wu, Q.
    Liu, J.
    Yang, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S645 - S645
  • [33] [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
    Verhoeff, Sarah R.
    Oosting, Sjoukje F.
    Elias, Sjoerd G.
    van Es, Suzanne C.
    Gerritse, Sophie L.
    Angus, Lindsay
    Heskamp, Sandra
    Desar, Ingrid M. E.
    van Oordt, C. Willemien Menke-van der Houven
    van der Veldt, Astrid A. M.
    Arens, Anne I. J.
    Brouwers, Adrienne H.
    Eisses, Bertha
    Mulders, Peter F. A.
    Hoekstra, Otto S.
    Zwezerijnen, Gerben J. C.
    van der Graaf, Winette T. A.
    Aarntzen, Erik H. J. G.
    Oyen, Wim J. G.
    van Herpen, Carla M. L.
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 592 - 601
  • [34] PET and MR imaging of the EPR effect with [89Zr]Zr-DFO-HSA in the CAM xenograft model: validation in comparison to murine xenografts and ex vivo data
    Hilbrig, Colmar
    Loeffler, Jessica
    Herrmann, Hendrik
    Solbach, Christoph
    Huber-Lang, Markus
    Rasche, Volker
    Beer, Ambros
    Winter, Gordon
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [35] 89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
    Kahts, Maryke
    Guo, Hua
    Kommidi, Harikrishna
    Yang, Yanping
    Sayman, Haluk Burcak
    Summers, Beverley
    Ting, Richard
    Zeevaart, Jan Rijn
    Sathekge, Mike
    Aras, Omer
    EJNMMI RADIOPHARMACY AND CHEMISTRY, 2023, 8 (01)
  • [36] 89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
    Maryke Kahts
    Hua Guo
    Harikrishna Kommidi
    Yanping Yang
    Haluk Burcak Sayman
    Beverley Summers
    Richard Ting
    Jan Rijn Zeevaart
    Mike Sathekge
    Omer Aras
    EJNMMI Radiopharmacy and Chemistry, 8
  • [37] THE EFFECT OF LABELLING APOLIPOPROTEIN (APO) A-1 WITH THE RADIO-ISOTOPE 89ZR ON CHOLESTEROL MOBILIZATION IN VITRO AND IN VIVO
    Sandberg, M.
    Barbaras, R.
    van Vught, D.
    Keijserling, C.
    Dasseux, J.
    Verberne, H.
    Smits, L.
    Dongen, G.
    Stroes, E.
    ATHEROSCLEROSIS, 2014, 235 (02) : E184 - E184
  • [38] Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET”
    René Raavé
    Gerwin Sandker
    Pierre Adumeau
    Christian Borch Jacobsen
    Floriane Mangin
    Michel Meyer
    Mathieu Moreau
    Claire Bernhard
    Laurène Da Costa
    Adrien Dubois
    Victor Goncalves
    Magnus Gustafsson
    Mark Rijpkema
    Otto Boerman
    Jean-Claude Chambron
    Sandra Heskamp
    Franck Denat
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 505 - 506
  • [39] Additional information on "Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET"
    Raave, Rene
    Sandker, Gerwin
    Adumeau, Pierre
    Jacobsen, Christian Borch
    Mangin, Floriane
    Meyer, Michel
    Moreau, Mathieu
    Bernhard, Claire
    Da Costa, Laurene
    Dubois, Adrien
    Goncalves, Victor
    Gustafsson, Magnus
    Rijpkema, Mark
    Boerman, Otto
    Chambron, Jean-Claude
    Heskamp, Sandra
    Denat, Franck
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (02) : 505 - 506
  • [40] Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT
    Walther, Martin
    Gebhardt, Peter
    Grosse-Gehling, Philipp
    Wuerbach, Lydia
    Irmler, Ingo
    Preusche, Stephan
    Khalid, Muhammad
    Opfermann, Thomas
    Kamradt, Thomas
    Steinbach, Joerg
    Saluz, Hans-Peter
    APPLIED RADIATION AND ISOTOPES, 2011, 69 (06) : 852 - 857